Last reviewed · How we verify
NCT03351855
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
Phase 1, PHASE2 trial testing HPV-CTLs in Human Papilloma Virus in 100 participants. Status unknown.
31 July 2019
Quick facts
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 15 November 2017 |
| Primary completion | 31 July 2019 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- HPV-CTLs — full drug profile →
Conditions studied
- Human Papilloma Virus — all drugs for Human Papilloma Virus →
Sponsor
Shenzhen Geno-Immune Medical Institute
Who can join
Adults 6 Months to 75, any sex, with Human Papilloma Virus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Harnessing virus-specific T cells: expanding therapeutic strategies across diverse populations.
Djassemi N, Hanisch B, Motta C, Maghzian N, et al · · 2025 · cited 2× · PMID 40864193 · DOI 10.1182/bloodadvances.2024013727
Verify or expand the search:
- PubMed search for NCT03351855
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Human Papilloma Virus
Currently open trials in the same condition.
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06414057 — HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT06598176 — Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples · NA · recruiting
- NCT05996783 — Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: ScreenUrSelf Trial · NA · active not recruiting
Other Shenzhen Geno-Immune Medical Institute trials
Trials by the same sponsor.
- NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
- NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
- NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03351855 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
- Last refreshed: 19 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03351855.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing